Skip to main content

Table 2 Resistance to cisplatin in each group and in two breast cell lines

From: RETRACTED ARTICLE: Inhibition of ZEB1-AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation

Groups

MCF-7

MDA-MB-231

IC50 (μmol/L)

IC50 (μmol/L)

Control

12.52 ± 1.17

14.63 ± 1.27

NC

13.12 ± 1.34

15.24 ± 1.31

si-ZEB1-AS1

7.89 ± 0.87*

6.57 ± 0.83*

miR-129-5p mimic

8.64 ± 0.94*

5.38 ± 0.75*

miR-129-5p inhibitor

19.65 ± 1.65*

22.84 ± 1.49*

si-ZEB1-AS1 + miR-129-5p mimic

4.06 ± 0.42*

2.26 ± 0.41*

  1. NC negative control, miR-129-5p microRNA-129-5p, ZEB1-AS1 zinc finger E-box binding homeobox 1 antisense 1
  2. *p < 0.05 vs. the control group
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us